证券代码：300143 证券简称：盈康生命 公告编号：2023-040 盈康生命科技股份有限公司 关于董事会换届选举的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 盈康生命科技股份有限公司（以下简称"公司"）第五届董事会任期即将届 满。为顺利完成本次董事会的换届选举（以下简称"本次换届选举"）工作，公司 董事会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 独立董事规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》和《公司章程》等有关规定，现将第六届董事会的组成、选举方式、 董事候选人的推荐、本次换届选举的程序以及董事候选人任职资格等事项公告如 下： 一、第六届董事会的组成 按照《公司章程》规定，公司第六届董事会由 7 名董事组成，其中独立董事 3 名，董事任期自股东大会选举通过之日起计算，任期三年。董事任期届满，可连选 连任，其中独立董事连任时间不得超过六年。 二、选举方式 本次换届选举采取累积投票制，即股东大会选举非独立董事或独立董事时，每 一股份拥有与拟选非独立董事或独立董事人数相同的表决 ...

证券代码：300143 证券简称：盈康生命 公告编号：2023-041 盈康生命科技股份有限公司 关于监事会换届选举的提示性公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 盈康生命科技股份有限公司（以下简称"公司"）第五届监事会任期即将届 满。为顺利完成本次监事会的换届选举（以下简称"本次换届选举"）工作，公司 监事会依据《中华人民共和国公司法》（以下简称"《公司法》"）和《公司章 程》等有关规定，现将第六届监事会的组成、选举方式、监事候选人的推荐、本 次换届选举的程序以及监事候选人任职资格等事项公告如下： 一、第六届监事会的组成 按照《公司章程》规定，公司第六届监事会由3名监事组成，其中职工代表 监事2名、股东代表监事1名。监事任期自股东大会选举通过之日起计算，任期三 年。监事任期届满，可连选连任。 二、选举方式 职工代表监事由公司职工代表大会选举或其他民主方式产生。非职工代表监 事由股东大会选举产生。 三、监事候选人的推荐（监事候选人推荐表见附件） （一）股东代表担任的监事候选人的推荐 民主选举产生。 四、本次换届选举的程序 （一）推荐人应在 202 ...

证券代码：300143 证券简称：盈康生命 公告编号：2023-036 1 72,788.82万元。上述募集资金已于2020年7月2日全部到账，由信永中和会计师事 务所（特殊普通合伙）对募集资金到位情况进 行了审验，并出具了 XYZH/2020GZA30231号《验资报告》。 二、2020 年度向特定对象发行股票募集资金监管协议的签订情况和募集资 金专户的开立情况 盈康生命科技股份有限公司 关于变更保荐机构后重新签订募集资金三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 盈康生命科技股份有限公司（以下简称"盈康生命"或"公司"）于2023年 7月12日披露了《关于变更保荐机构及保荐代表人的公告》（公告编号：2023-034）， 公司聘请国泰君安证券股份有限公司（以下简称"国泰君安"）担任公司2022年 度向特定对象发行股票（以下简称"本次发行"）的保荐机构，具体负责公司本 次发行的保荐工作及证券上市后的持续督导工作，公司与原保荐机构安信证券股 份有限公司（以下简称"安信证券"）因2020年度向特定对象发行股票事项签订 的保荐协议终止，安信证 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥361,417,574.60, representing a 35.09% increase compared to ¥267,547,194.29 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥39,550,000.16, a 64.07% increase from ¥24,105,210.83 year-on-year[4] - The basic earnings per share for Q1 2023 was ¥0.0616, up 64.27% from ¥0.0375 in Q1 2022[5] - Total operating revenue for Q1 2023 was CNY 361,417,574.60, an increase of 35.0% compared to CNY 267,547,194.29 in Q1 2022[30] - Net profit for Q1 2023 reached CNY 39,591,017.54, up 48.0% from CNY 26,705,857.97 in the same period last year[31] - Operating profit for the quarter was CNY 47,469,023.13, representing a 35.2% increase from CNY 35,100,174.65 in Q1 2022[30] - The weighted average return on equity for Q1 2023 was 3.04%, up from 1.35% in the same period last year[5] Cash Flow and Assets - The company reported a cash flow from operating activities of ¥38,669,216.63, an increase of 7.82% compared to ¥35,865,963.18 in the previous year[4] - Cash generated from operating activities was CNY 356,067,966.47, an increase from CNY 295,614,194.14 in the same quarter last year[33] - The net cash flow from operating activities for Q1 2023 was ¥38,669,216.63, an increase from ¥35,865,963.18 in Q1 2022, reflecting a growth of approximately 4.5%[34] - Total assets at the end of Q1 2023 were ¥2,106,624,880.96, reflecting a 3.09% increase from ¥2,027,856,490.51 at the end of the previous year[5] - As of March 31, 2023, total assets amounted to RMB 2,106.62 million, an increase from RMB 2,043.51 million at the beginning of the year[28] - Cash and cash equivalents decreased to RMB 412.69 million from RMB 433.18 million at the beginning of the year, reflecting a decline of approximately 4.3%[27] Investments and Research - The company launched 21 new technologies and projects in the medical field during the reporting period, focusing on enhancing diagnostic and treatment capabilities[9] - Research and development expenses increased to CNY 12,728,463.50, a rise of 158.5% compared to CNY 4,916,338.15 in the previous year[30] - The company is focusing on expanding its investment in biotechnology, medical devices, and high-end equipment through partnerships with investment institutions[23] - The total investment for the medical device smart ecosystem project is estimated at RMB 566.11 million, funded by self-owned and self-raised funds[22] Market and Product Development - Internet medical revenue grew by 205% year-on-year, reaching ¥15,520,000 in Q1 2023[11] - The company's infusion products market share increased to 8.14%, ranking fourth in 2022, with sales growth of 304% year-on-year due to the post-pandemic ICU expansion[14] - The company received four new scientific research certificates for its breast imaging products, enhancing its reputation and development capabilities in high-end breast imaging diagnostic equipment[15] - The company launched a complete solution for future hospital scenarios, optimizing seven key areas including nursing treatment and environmental control, establishing an industry brand[13] - The company’s new temperature management product, a medical warming blanket, received registration approval, aimed at reducing heat loss during surgery and shortening recovery time[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,810, with the largest shareholder, Qingdao YK Medical Investment Co., Ltd., holding 39.69% of shares[17] - The company plans to fully unlock executive restricted shares by March 13, 2024, with a total of 7,875 shares for one executive and 5,625 shares for another[21] - The company’s stockholder Ji Zihao holds a total of 8,312,457 shares, including shares held through a margin trading account[19] Liabilities and Financial Position - Total liabilities as of the end of Q1 2023 were CNY 755,215,518.01, up from CNY 726,165,177.60 at the end of Q1 2022[30] - The company's total equity increased to CNY 1,351,409,362.95, compared to CNY 1,317,343,672.12 in the previous year[30] - Current liabilities include short-term borrowings of RMB 15.82 million, down from RMB 16.72 million, a decrease of about 5.4%[28] - Accounts payable increased to RMB 160.78 million from RMB 147.75 million, representing an increase of approximately 8.8%[28] Cash Flow Activities - Total cash inflow from operating activities amounted to ¥363,282,348.43, compared to ¥301,270,724.17 in the previous year, indicating a year-over-year increase of about 20.6%[34] - Cash outflow from operating activities was ¥324,613,131.80, up from ¥265,404,760.99 in Q1 2022, representing an increase of approximately 22.3%[34] - The net cash flow from investing activities was -¥57,320,837.17, worsening from -¥11,994,538.38 in the same quarter last year[34] - Cash outflow for investing activities reached ¥59,320,870.17, significantly higher than ¥12,056,846.38 in Q1 2022[34] - The net cash flow from financing activities was -¥1,690,284.22, compared to -¥3,724,861.11 in Q1 2022, showing an improvement of approximately 54.7%[35] - The total cash and cash equivalents at the end of Q1 2023 were ¥412,685,925.67, down from ¥681,641,103.56 at the end of Q1 2022, a decrease of about 39.5%[35] Miscellaneous - The company did not conduct an audit for the Q1 2023 report[36] - The company expanded its clinical promotion of the shortwave therapy device to several hospitals, including Xiangya Hospital and Shanghai First Maternity and Infant Hospital[15] - The company is focusing on digital therapies and home health monitoring systems to enhance patient care and recovery management[13]

证券代码：300143 证券简称：盈康生命 投 资 者 关 系活 动类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 其他 参 与 单 位 名称 及人员姓名 通过全景网"投资者关系互动平台"参加公司"2022 年度报 告网上业绩说明会"的投资者。 时间 2023 年 3 月 31 日 15：00-17：00 地点 全景网"投资者关系互动平台" （https://rs.p5w.net） 上 市 公 司 接待 人员姓名 董事兼总经理 彭 文 独立董事 卢 军 财务总监 谈 波 董事会秘书 刘泽霖 投 资 者 关 系活 动 主 要 内 容介 绍 盈康生命科技股份有限公司（以下简称"公司"）于 2023 年 3 月 31 日下午 15：00-17：00 通过全景网"投资 者关系互动平台"举行 2022 年度报告网上业绩说明会，本 次业绩说明会采用网络远程的方式举行，业绩说明会问答 环节主要内容如下： 1、公司目前在数字化领域的进展和成果如何？ 回答：尊敬的投资者，您好！公司构筑数字化治理/数 字化体验/数字疗法应用的平台。数字化治理方面，利用数 字化手段构筑公司整体的数 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,156,246,284.05, representing a 6.09% increase compared to ¥1,089,867,456.38 in 2021[20]. - The net profit attributable to shareholders was -¥595,918,136.20, a decline of 63.68% from -¥364,080,340.52 in the previous year[20]. - The net cash flow from operating activities increased by 27.91% to ¥160,671,681.77, up from ¥125,613,690.73 in 2021[20]. - The basic and diluted earnings per share were both -¥1.01, a decrease of 77.19% compared to -¥0.57 in 2021[20]. - The weighted average return on net assets was -39.99%, down from -15.32% in the previous year[20]. - The company reported a net profit excluding non-recurring gains and losses of -¥596,982,477.33, a 26.03% increase in losses compared to -¥473,673,471.11 in 2021[20]. - Total assets decreased by 18.00% to CNY 2,027,856,490.51 at the end of 2022 compared to CNY 2,473,064,924.99 at the end of 2021[21]. - The total net assets attributable to shareholders decreased by 27.66% to CNY 1,283,089,099.25 at the end of 2022 from CNY 1,773,580,427.79 at the end of 2021[21]. - The company reported a significant drop in net profit in Q4 2022, with a loss of CNY -651,430,308.93 compared to profits in the first three quarters[23]. Operational Challenges - The company has acknowledged the need for measures to improve profitability due to the negative net profit[4]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the audit report for the most recent year[21]. - The net profit after deducting non-recurring gains and losses was negative for the last three accounting years, indicating ongoing operational challenges[21]. - The company is positioned to benefit from the increasing demand for healthcare services as pandemic-related restrictions ease and overall hospital utilization rates are expected to recover[45]. Government Support and Market Outlook - The company received government subsidies amounting to CNY 6,459,261.55 in 2022, up from CNY 2,615,808.22 in 2021, indicating increased support for operations[27]. - The domestic tumor medical service market is expected to grow significantly, with private tumor hospitals projected to reach revenue of CNY 106.7 billion by 2025, contributing to an overall market growth to CNY 700.3 billion at a CAGR of 12.5%[42]. - The medical device industry in China is anticipated to maintain rapid growth due to rising living standards, an aging population, and strong government support, with significant revenue increases expected in various segments[43]. - The government has emphasized the importance of grassroots healthcare, aiming to enhance service capabilities in community hospitals and health centers during the 14th Five-Year Plan period[35]. Product Development and Innovation - The company invested ¥28,030,000 in R&D during the reporting period, with a total of 101 patents applied for, including 54 invention patents[85]. - The number of innovative medical devices approved for market in 2022 increased by 57.1% year-on-year, with a total of 55 products approved[51]. - The company has developed a digital governance platform to improve operational efficiency across hospitals, including a unified standard operating platform for supply chain management[83]. - The company is currently developing a head-and-body integrated knife and a linear accelerator, aiming to enhance its product line and market competitiveness[109]. Acquisitions and Partnerships - The company completed acquisitions of Hebei Ailikesen and Shenzhen Saintno Medical, enhancing its R&D capabilities and product offerings[62]. - The acquisition of Hebei Ailikesen Medical Technology Co., Ltd. allowed the company to expand into rehabilitation technology, enhancing its service capabilities in the oncology treatment sector[147]. - The company has formed partnerships with several medical universities to promote technological innovation and enhance specialty capabilities in oncology[57]. Digital Health and Service Expansion - The company established a digital health management platform "Experience Cloud," achieving 1,040,000 online orders, a 765% year-over-year increase, and 100% coverage of inpatient-outpatient patients at Friendship Hospital[61]. - The company is expanding its digital health services, including home delivery of medications and online consultations, enhancing patient satisfaction and engagement[60]. - The company is focusing on building a digital interactive service network to enhance home healthcare solutions[70]. Financial Management and Governance - The company reported a total of ¥137,743,243.76 in sales from its top five customers, which constitutes 11.91% of the annual total sales[105]. - The total procurement amount from the top five suppliers was ¥245,026,115.65, accounting for 57.79% of the annual total procurement[106]. - The company has implemented measures to mitigate potential competition with its controlling shareholder, including management agreements and asset transfers[174]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[172]. Future Strategies and Goals - The company plans to develop a breast and brain tumor center in 2023, focusing on enhancing its digital capabilities and optimizing revenue structures[150]. - The company aims to accelerate the development of a comprehensive cancer prevention, diagnosis, treatment, and rehabilitation ecosystem, focusing on innovation and user-centered services[92]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[179]. - The company has set a revenue guidance of 1.8 billion RMB for 2023, indicating a growth target of 20%[181].

证券代码：300143 证券简称：盈康生命 公告编号：2023-013 盈康生命科技股份有限公司 关于举行 2022 年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 盈康生命科技股份有限公司（以下简称"公司"）将于 2023 年 3 月 30 日在巨潮资 讯网（http://www.cninfo.com.cn）披露《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更加深入、全面地了解公司 2022 年度经营情况，公司定于 2023 年 3 月 31 日（星期五）下午 15:00-17:00 在全景网举行 2022 年度报告网上业绩说明会。本次 业绩说明会将采用网络远程的方式举行，投资者可在上述时间段内登录全景网"投资者 关系互动平台"（https://ir.p5w.net）参与 2022 年度业绩说明会。 目前拟出席本次年度报告说明会的人员有：公司董事兼总经理彭文先生、独立董事 卢军先生、财务总监谈波先生、董事会秘书刘泽霖先生，具体以当天实际出席会员为准。 为充分尊重投资者、提升交流的针对性，现就公司202 ...